UAE Fertility Testing Devices Market Industry Size, Share, Trends, Opportunity, and Forecast Segmented by Product Type (Ovulation Prediction Kits, Fertility Monitors (Urine-based Ovulation Test, Saliva-based Ovulation Test), Male Fertility Testing Products), By Application (Female Fertility Testing, Male Fertility Testing), By Mode of Purchase (OTC, Prescription-based), By End User (Hospitals, Fertility Clinics, Home Care Settings), by region, and Competition 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 26.91 Million
CAGR (2026-2031)	8.89%
Fastest Growing Segment	Hospitals
Largest Market	Abu Dhabi
Market Size (2031)	USD 44.86 Million

Market Overview

The UAE Fertility Testing Devices Market will grow from USD 26.91 Million in 2025 to USD 44.86 Million by 2031 at a 8.89% CAGR. Fertility testing devices comprise diagnostic instruments such as ovulation prediction kits, fertility monitors, and sperm analyzers that enable individuals to track reproductive hormones and determine fertile windows. The market in the United Arab Emirates is primarily driven by the increasing prevalence of lifestyle-related infertility and a demographic shift towards delayed parenthood among the resident population. Furthermore, the recent expansion of mandatory health insurance policies to cover reproductive treatments actively supports the growing demand for both home-based and clinical diagnostic solutions by reducing the overall financial burden on patients.

However, the market confronts a significant challenge regarding the high cost of advanced digital monitoring systems which restricts accessibility for price-sensitive consumer segments. This economic barrier remains pertinent even as regional clinical capabilities advance to world-class standards. According to the Department of Health – Abu Dhabi, in 2025, the sector achieved a success rate surpassing 51 percent for assisted reproductive procedures. While this figure demonstrates the high efficacy of available medical interventions, the premium pricing of the requisite preliminary testing devices continues to impede broader market expansion across diverse socioeconomic groups.

Key Market Drivers

The increasing prevalence of infertility and lifestyle-related disorders acts as a primary catalyst for the UAE Fertility Testing Devices Market. Rapid urbanization has led to sedentary lifestyles and rising obesity rates among the local population, compelling individuals to seek early reproductive diagnostics to address conception challenges. As couples encounter difficulties in natural conception, the demand for ovulation monitors and sperm analysis kits escalates as a preliminary step before undergoing invasive medical procedures. This demographic pressure is quantitatively evident; according to The National News, August 2025, in the 'New fertility treatments offer hope of reversing declining birth rates in UAE', the fertility rate in the country has dropped significantly to just 1.21 live births per woman in 2024. Consequently, this sharp decline necessitates widespread utilization of diagnostic tools to identify reproductive windows and underlying health barriers efficiently.

Simultaneously, the expansion of specialized fertility clinics and medical tourism infrastructure significantly amplifies market growth. The UAE has positioned itself as a regional hub for reproductive medicine, attracting international patients who require high-precision diagnostics as part of their treatment protocols. This robust clinical ecosystem supports the deployment of professional-grade testing devices while normalizing the use of home-based monitoring solutions for ongoing patient management. According to the Department of Health – Abu Dhabi, February 2025, in the 'DoH Reports 695 Childbirths via IVF in 2024', specialized healthcare facilities in the emirate recorded 695 childbirths through IVF in 2024, reflecting the high volume of clinical activity that necessitates continuous hormonal tracking. Furthermore, the broader scope of the market is highlighted by the total natality volume; according to Gulf Today, in 2025, the total number of births in Abu Dhabi reached 39,333 in 2024, indicating a substantial baseline population requiring reproductive health management and preliminary fertility testing.

Download Free Sample Report

Key Market Challenges

The high acquisition cost of advanced digital fertility monitors creates a substantial economic barrier that significantly impedes market penetration across the broader population of the United Arab Emirates. While these devices offer superior accuracy and data integration compared to traditional methods, their premium pricing models effectively alienate price-sensitive consumer groups. This financial disparity limits the primary customer base to affluent demographics and prevents the mass adoption required for substantial market volume growth. Consequently, a large segment of the residents is forced to rely on less reliable analog alternatives or forego home-based testing entirely, which reduces the potential revenue stream for manufacturers.

This restriction on accessibility is particularly detrimental given the critical necessity for reproductive health monitoring in the region. The disconnection between high clinical demand and product affordability results in a stagnant conversion rate of potential users into actual buyers. According to the Dubai Health Authority, in 2024, around 50 percent of women in the United Arab Emirates faced issues pertaining to infertility. This statistic underscores the vast addressable market that remains largely untapped because the requisite diagnostic tools are financially out of reach for many, directly hampering the overall sector expansion.

Key Market Trends

The Rapid Adoption of AI-Enabled Diagnostic Tools is fundamentally altering the UAE Fertility Testing Devices Market by enhancing the precision of reproductive technologies. Clinical facilities are increasingly integrating machine learning algorithms into sperm analyzers and oocyte assessment software to automate labor-intensive processes. This technological shift addresses male factor infertility more effectively than manual methods, directly driving the procurement of AI-integrated diagnostic workstations. According to WAM, August 2025, in the 'AI achieves breakthrough in infertility treatment in Dubai', the deployment of the SpermSearchAI system reduced the duration of sperm detection procedures by approximately 50 percent. Such efficiency gains are compelling healthcare providers to upgrade their diagnostic infrastructure, thereby sustaining demand for advanced algorithmic testing solutions.

Concurrently, the Expansion of Direct-to-Consumer (DTC) At-Home Testing Services is decentralizing market access by enabling patients to conduct hormone profiling outside clinical settings. This trend prioritizes privacy and convenience, fostering a new revenue stream for manufacturers of portable blood collection kits and digital analysis platforms. The viability of this model is evidenced by significant capital inflows into regional femtech enterprises that bundle diagnostic hardware with telehealth support. According to Health Tech World, July 2025, in the 'UAE femtech firm raises US$1.2m pre-seed funding', the startup Ovasave secured $1.2 million to accelerate the distribution of its at-home fertility testing services. This investment underscores the growing consumer preference for remote diagnostic modalities over traditional hospital-based screening.

Segmental Insights

The Hospitals segment is currently identifying as the fastest-growing category within the UAE fertility testing devices market due to substantial investments in healthcare infrastructure and a rising preference for professional diagnostic accuracy. This expansion is supported by regulatory frameworks from the Ministry of Health and Prevention that encourage the integration of specialized reproductive medicine units within major medical facilities. Furthermore, patients increasingly prioritize hospital-based testing for its reliability and the immediate availability of specialist consultation. Consequently, the broadening network of multi-specialty hospitals across the Emirates drives the accelerated adoption of professional fertility testing systems.

Regional Insights

Abu Dhabi holds a dominant position in the UAE fertility testing devices market, driven by strategic government initiatives and a supportive healthcare infrastructure. The Department of Health – Abu Dhabi actively implements regulations that standardize fertility treatments, thereby fostering trust and adoption of diagnostic tools. Furthermore, the region benefits from comprehensive insurance coverage for nationals under the Thiqa program, which significantly increases the accessibility of assisted reproductive services and necessary preliminary testing. This combination of favorable reimbursement policies and a concentration of specialized clinics ensures consistent demand for fertility monitoring solutions within the emirate.

Recent Developments

• In November 2025, M42 and the private equity firm Olive Rock Partners announced the completion of a strategic realignment of their healthcare assets in the UAE. Under this agreement, Olive Rock Partners assumed full ownership of HealthPlus IVF and Women’s Health Abu Dhabi, including its associated genetics laboratory and pharmacy. This transaction was designed to enable dedicated investment in reproductive medicine and genetics, fostering further innovation in fertility testing and treatment services. The separation allowed the fertility division to operate with greater autonomy, aiming to position Abu Dhabi as a leading global destination for advanced reproductive care and specialized genetic diagnostics.
• In January 2025, Nabta Health entered into a strategic partnership with Clemenceau Medical Center Hospital Dubai to establish a Women's Health Clinical Center of Excellence. This collaboration was formed to deliver a comprehensive suite of female-focused healthcare services, including specialized fertility treatments, perinatal care, and menopause management. The center integrated Nabta Health’s advanced digital health platform and diagnostic pathways with the hospital's clinical infrastructure. This development represented a significant step in hybrid healthcare delivery, combining physical testing facilities with remote monitoring technologies to enhance patient outcomes in the fertility and women's health sector.
• In September 2024, Ovasave, a UAE-based femtech startup, collaborated with the pharmaceutical company Merck Gulf to launch a nationwide awareness initiative titled "Fertility Your Way." This campaign featured a mobile screening bus that traveled across Dubai and Abu Dhabi, offering complimentary Anti-Müllerian Hormone (AMH) testing to women. The initiative aimed to educate the public about ovarian reserves and reproductive health, facilitating early diagnosis and informed decision-making regarding fertility preservation. This strategic partnership underscored the growing demand for accessible fertility testing devices and highlighted the role of corporate collaborations in driving market penetration for diagnostic solutions.
• In June 2024, HealthPlus Fertility, a subsidiary of the M42 group, inaugurated a specialized facility dedicated to men's reproductive health in Abu Dhabi. Named the HOWA Men’s Health Clinic, this establishment was designed to address male fertility issues, hormonal imbalances, and andrology concerns in a private, supportive setting. The launch coincided with International Men's Health Week and aimed to destigmatize male infertility testing and treatment. By offering comprehensive diagnostic services and personalized care plans, the clinic sought to encourage men to proactively manage their reproductive well-being, thereby expanding the market for specialized fertility testing and monitoring solutions in the region.

Key Market Players

• Abbott Laboratories SA
• Quidel Corporation
• Procter & Gamble Middle East FZE
• Fairhaven Health, LLC
• Church & Dwight Co., Inc.
• SPD Swiss Precision Diagnostics GmbH
• Procter & Gamble Co.
• Eli Lilly and Company
• Thermo Fisher Scientific Inc.
• Roche Diagnostics
• Geratherm Medical AG

By Application	By Mode of Purchase	By End User	By Region
Female Fertility Testing Male Fertility Testing	OTC Prescription-based	Hospitals Fertility Clinics Home Care Settings	Dubai Abu Dhabi Sharjah Rest of UAE

Report Scope:

In this report, the UAE Fertility Testing Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• UAE Fertility Testing Devices Market, By Application:

• Female Fertility Testing
• Male Fertility Testing

• UAE Fertility Testing Devices Market, By Mode of Purchase:

• OTC
• Prescription-based

• UAE Fertility Testing Devices Market, By End User:

• Hospitals
• Fertility Clinics
• Home Care Settings

• UAE Fertility Testing Devices Market, By Region:

• Dubai
• Abu Dhabi
• Sharjah
• Rest of UAE